A randomization-based theory for preliminary testing of covariate balance in controlled trials

IF 1.5 4区 医学 Q3 MATHEMATICAL & COMPUTATIONAL BIOLOGY Statistics in Biopharmaceutical Research Pub Date : 2023-10-13 DOI:10.1080/19466315.2023.2267774
Anqi Zhao, Peng Ding
{"title":"A randomization-based theory for preliminary testing of covariate balance in controlled trials","authors":"Anqi Zhao, Peng Ding","doi":"10.1080/19466315.2023.2267774","DOIUrl":null,"url":null,"abstract":"AbstractRandomized trials balance all covariates on average and are the gold standard for estimating treatment effects. Chance imbalances nevertheless exist more or less in realized treatment allocations and intrigue an important question: what should we do if the treatment groups differ with respect to some important baseline characteristics? A common strategy is to conduct a preliminary test of the balance of baseline covariates after randomization, and invoke covariate adjustment for subsequent inference if and only if the realized allocation fails some prespecified criterion. Although such practice is intuitive and popular among practitioners, the existing literature has so far only evaluated its properties under strong parametric model assumptions in theory and simulation, yielding results of limited generality. To fill this gap, we examine two strategies for conducting preliminary test-based covariate adjustment by regression, and evaluate the validity and efficiency of the resulting inferences from the randomization-based perspective. The main result is twofold. First, the preliminary-test estimator based on the analysis of covariance can be even less efficient than the unadjusted difference in means, and risks anticonservative confidence intervals based on normal approximation even with the robust standard error. Second, the preliminary-test estimator based on the fully interacted specification is less efficient than its counterpart under the always-adjust strategy, and yields overconservative confidence intervals based on normal approximation. In addition, although the Fisher randomization test is still finite-sample exact for testing the sharp null hypothesis of no treatment effect on any individual, it is no longer valid for testing the weak null hypothesis of zero average treatment effect in large samples even with properly studentized test statistics. These undesirable properties are due to the asymptotic non-normality of the preliminary-test estimators. Based on theory and simulation, we echo the existing literature and do not recommend the preliminary-test procedure for covariate adjustment in randomized trials.Keywords: Causal inferencedesign-based inferenceefficiencyFisher randomization testregression adjustmentrerandomizationDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. FundingThe author(s) reported there is no funding associated with the work featured in this article.","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":"46 1","pages":"0"},"PeriodicalIF":1.5000,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19466315.2023.2267774","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

AbstractRandomized trials balance all covariates on average and are the gold standard for estimating treatment effects. Chance imbalances nevertheless exist more or less in realized treatment allocations and intrigue an important question: what should we do if the treatment groups differ with respect to some important baseline characteristics? A common strategy is to conduct a preliminary test of the balance of baseline covariates after randomization, and invoke covariate adjustment for subsequent inference if and only if the realized allocation fails some prespecified criterion. Although such practice is intuitive and popular among practitioners, the existing literature has so far only evaluated its properties under strong parametric model assumptions in theory and simulation, yielding results of limited generality. To fill this gap, we examine two strategies for conducting preliminary test-based covariate adjustment by regression, and evaluate the validity and efficiency of the resulting inferences from the randomization-based perspective. The main result is twofold. First, the preliminary-test estimator based on the analysis of covariance can be even less efficient than the unadjusted difference in means, and risks anticonservative confidence intervals based on normal approximation even with the robust standard error. Second, the preliminary-test estimator based on the fully interacted specification is less efficient than its counterpart under the always-adjust strategy, and yields overconservative confidence intervals based on normal approximation. In addition, although the Fisher randomization test is still finite-sample exact for testing the sharp null hypothesis of no treatment effect on any individual, it is no longer valid for testing the weak null hypothesis of zero average treatment effect in large samples even with properly studentized test statistics. These undesirable properties are due to the asymptotic non-normality of the preliminary-test estimators. Based on theory and simulation, we echo the existing literature and do not recommend the preliminary-test procedure for covariate adjustment in randomized trials.Keywords: Causal inferencedesign-based inferenceefficiencyFisher randomization testregression adjustmentrerandomizationDisclaimerAs a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also. FundingThe author(s) reported there is no funding associated with the work featured in this article.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对照试验中协变量平衡初步检验的随机化理论
随机试验平均平衡所有协变量,是估计治疗效果的金标准。然而,机会不平衡或多或少地存在于已实现的治疗分配中,并引发了一个重要的问题:如果治疗组在一些重要的基线特征方面存在差异,我们该怎么办?一种常见的策略是在随机化后对基线协变量的平衡进行初步测试,当且仅当实现的分配不符合某些预先规定的标准时,调用协变量调整以进行后续推断。虽然这种做法是直观的,在从业者中很受欢迎,但迄今为止,现有文献仅在理论和仿真中对其性质进行了强参数化模型假设的评估,结果的通用性有限。为了填补这一空白,我们研究了两种策略,通过回归进行初步的基于测试的协变量调整,并从基于随机化的角度评估所得推断的有效性和效率。主要结果是双重的。首先,基于协方差分析的初步检验估计量甚至比未经调整的均值差更低效,并且即使具有稳健的标准误差,也存在基于正态近似的反保守置信区间的风险。其次,基于完全交互规范的预测试估计器的效率低于始终调整策略下的预测试估计器,并且产生基于正态近似的过度保守置信区间。此外,尽管Fisher随机化检验对于检验对任何个体没有治疗效果的尖锐零假设仍然是有限样本精确的,但即使使用适当的学生化检验统计量,它也不再适用于检验大样本中平均治疗效果为零的弱零假设。这些不良性质是由于初步检验估计量的渐近非正态性。基于理论和模拟,我们赞同现有文献,不推荐随机试验中协变量调整的初步检验程序。关键词:因果推理基于设计的推理效率fisher随机化检验回归调整随机化免责声明作为对作者和研究人员的服务,我们提供此版本的已接受稿件(AM)。在最终出版版本记录(VoR)之前,将对该手稿进行编辑、排版和审查。在制作和印前,可能会发现可能影响内容的错误,所有适用于期刊的法律免责声明也与这些版本有关。作者报告说,没有与本文所述工作相关的资金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY
CiteScore
3.90
自引率
16.70%
发文量
56
期刊介绍: Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.
期刊最新文献
A Basket Trial Design Based on Power Priors Remembering Gregory Campbell (1949-2023): An Accomplished Leader, Mentor, and Biostatistical Innovator Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials Bayesian shrinkage estimation of credible subgroups for count data with excess zeros
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1